Karita, E., Nyombayire, J., Ingabire, R., Mazzei, A., Sharkey, T., Mukamuyango, J., . . . Wall, K. M. (2022). Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: Study protocol for a phase 3 open-label randomized controlled trial. Current controlled trials in cardiovascular medicine, 23(1), 513-23. https://doi.org/10.1186/s13063-022-06360-3
Citácia podle Chicago (17th ed.)Karita, Etienne, et al. "Safety, Reactogenicity, and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Adult Pregnant Women: Study Protocol for a Phase 3 Open-label Randomized Controlled Trial." Current Controlled Trials in Cardiovascular Medicine 23, no. 1 (2022): 513-23. https://doi.org/10.1186/s13063-022-06360-3.
Citácia podľa MLA (8th ed.)Karita, Etienne, et al. "Safety, Reactogenicity, and Immunogenicity of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Adult Pregnant Women: Study Protocol for a Phase 3 Open-label Randomized Controlled Trial." Current Controlled Trials in Cardiovascular Medicine, vol. 23, no. 1, 2022, pp. 513-23, https://doi.org/10.1186/s13063-022-06360-3.